We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I do hope not! I rather hope the SP follows the progress AVCT say they are making - not what they may or may not be actually making. As we have seen many times previously - the two are not necessarily the same thing. All depends if you believe what AS says - I no longer believe a word he says until there is incontrovertible proof to support his utterings.
"It is doing what it is designed to do" - Christina Coughlin (c.22 minutes into presentation).
That will do for me!
Given volume of late Heights latest batch must be almost done and then SP should be free to start following the fundamental progress the company are making
A bb observation from a reader who posts little: yesterday many of the posts here were titled 'Has to kiss the 38p level...' and 'Nothing the Company can say will stop the slide...'. As far as I can see both of these threads were started by the same poster (posting history reveals a serial shorter posting in a plethora of shares). Whilst I acknowledge the open nature of bbs I do think that yesterday our own lths performed most of the deramping actions by perpetuating the use of openly deramping thread titles (they are even in BOLD for heaven's sake). I feel that any thread title should be read and assessed before just using it to post. I have used a neutral thread title here which should even be acceptable to our resident trolls. Let's 'AIM' to keep the board at least as much for us who are invested here as for those who wish us ill. As ever, VGLA
Bella
Agree with all your points but we will only know when arm2 results are analysed
"The phase 1 trial aimed to investigate the efficacy and safety of AVA6000 in patients with FAP-positive solid tumors, focusing on targeted delivery and therapeutic outcomes."
So, not your normal tolerability and safety Phase 1 trial then. Stopped reading after that.
Could those believing this is a peer reviewed article please explain their reasoning, preferably by interpretive dance for my added amusement.
When are you going to come back onto the KOD board and explain why it hasn't fallen through the 0.2s as you predicted.
In fact it is more than twice your predicted price.
Same will happen here
Https://avacta.wistia.com/medias/b74537ezmn
This presentation rather tucked away in the ‘ other resources’.
It’s the most telling summary delivered well.
Investors should review .
Sound.
The immediate priority is to commercialise the pre|CISIONTM platform.
For those that have the where·withal & foresight to see it through should eventually be a win/win for everyone involved .
The goals of the company need updating but some still valid (albeit execution so far somewhat open to question -fair enough )
---------------
"Our mission is to improve patients’ lives and grow shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. Clear communication of our corporate objectives and keeping our shareholders up to date with progress, as well as informing potential new investors about the investment opportunity, is at the core of our communications programme. I hope you find the information you are looking for and welcome any feedback
ALASTAIR SMITH, CHIEF EXECUTIVE OFFICER"
The immediate priority is to commercialise the pre|CISIONTM platform.
For those that have the where·withal & foresight to see it through should eventually be a win/win for everyone involved .
The goals of the company need updating but some still valid (albeit execution so far somewhat open to question -fair enough )
---------------
"Our mission is to improve patients’ lives and grow shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. Clear communication of our corporate objectives and keeping our shareholders up to date with progress, as well as informing potential new investors about the investment opportunity, is at the core of our communications programme. I hope you find the information you are looking for and welcome any feedback
ALASTAIR SMITH, CHIEF EXECUTIVE OFFICER"
AS always said that it was important that any trial results were peer reviewed... and there you have it in black and white a positive peer review.
Good find by https://twitter.com/Mstambo999 , great summary.
Importantly, published in the ‘Onc Weekly’ segment of ‘Physicians Weekly’ and headlining Prof Banerji, our AACR24 poster presenter and Deputy Director at The ICR and Royal Marsden.
“U. Banerji and the team aimed to assess the efficacy and safety of AVA6000 in FAP-positive solid tumors. Preliminary results indicated promising antitumor activity and support ongoing dose escalation studies to further evaluate its potential in clinical settings.”
Looks like progress to date now being ‘owned’ by top oncology clinicians.
GLA
These shorts are in control right now
I wonder who will be the first troll to take this from the top spot !
Brilliant article !
Naturally we all talk from an Investors perspective, many working to develop new areas of science their motivation can be quite different. AS doesn’t strike me as someone who’s only interested in financial gain thus this vehicle we’re in may not hold the resale valve some expect !
Good article
What they are forgetting is the company doesn’t r its to cure cancer (would be nice though) it exists to generate value for its owners. When you start losing 50 60 70% of value then you have to have a change of perspective. We aren’t the only company working in this area.
I have been here more years than I care to remember. I posted that when Al bought his big house for his wife, it proved then as it does now, Al might be a good scientist but as for being a business, please do not go there. We have all been made poorer by AL and no matter what RAH and Myles might say, I will apologise, to AL if I can recover my substantial losses. Based on the current price, if an offer came along for our technology, it would not surprise if Al said' Yours for 50p per share mate'..Al is incompetent as a CEO and we know it. Best
"KEY TAKEAWAYS
The phase 1 trial aimed to investigate the efficacy and safety of AVA6000 in patients with FAP-positive solid tumors, focusing on targeted delivery and therapeutic outcomes.
Researchers noticed significant antitumor activity in FAP-positive tumors due to high doxorubicin concentrations in the TME, which supports AVA6000 efficacy."
FYI : Courtesy of twitter ;
PhysiciansWeekly
https://oncweekly.com/ava6000-targeted-doxorubicin-delivery-for-antitumor-activity/
FYI
"Launch Diagnostics France SASLaunch Diagnostics France SAS
220 followers220 followers
15h • 15h •
Follow
Le 25 avril est la journée mondiale de lutte contre le paludisme
Plus de 240 millions de cas de paludisme sont recensés chaque année, cette maladie mortelle a tué plus de 600 000 personnes en 2022 dans 60 pays différents.
Le déploiement du premier vaccin contre le paludisme approuvé par l'OMS est un réel espoir dans cette lutte.
En France, on compte environ 5500 cas d’importation chaque année. Dans son dernier point épidémiologique, Santé Publique France indique que 22 cas de paludisme importés ont été signalés à La Réunion, seulement au cours du premier trimestre 2024.
La Journée Mondiale de Lutte contre le Paludisme est donc une opportunité de renouveler notre engagement dans le diagnostic de cette maladie.
hashtag#malaria hashtag#paludisme hashtag#biologiemoléculaire hashtag#POC
…see more
Rate this translation
April 25 is World Malaria Day
More than 240 million cases of malaria are recorded each year, this deadly disease killed more than 600,000 people in 2022 in 60 different countries.
The rollout of the first malaria vaccine approved by the WHO is a real hope in this fight.
In France, there are about 5500 cases of importation each year. In its latest epidemiological update, Santé Publique France indicates that 22 cases of imported malaria have been reported in Reunion Island alone, only during the first quarter of 2024.
World Malaria Day is therefore an opportunity to renew our commitment to the diagnosis of this disease.
hashtag#malaria hashtag#paludisme hashtag#biologiemoléculaire hashtag#POC"
Charts are total rubbish. You can make read however you want !
Says the investment expert who boasts about being in at 68 p when the share price is 43 p
No we won’t take your advice just at the moment
LD & Coris both attending conference . 𝗘𝗖𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 is approaching fast
Manufactuers offer a wide range of products that LD distibute
e.g , https://www.launchdiagnostics.com/products/
--------
Topfeed updates
Feed post number 1
View Launch Diagnostics Limited
Launch Diagnostics Limited likes this
Anatolia Geneworks
Anatolia GeneworksAnatolia Geneworks
5,047 followers5,047 followers
5d • 5d •
Follow
World Liver Day celebrated on the 19th of April, plays a vital role in raising awareness of chronic liver diseases.
The liver is one of the most vital organs in the human body which performs more than 500 complex functions.
Unfortunately, there are many chronic liver-related disease and 2 million people lose their lives each year from them. 1.5 billion people suffer from chronic liver diseases and 90% of the cases are preventable. One of the chronic liver diseases is viral hepatitis which comprises Hepatitis B (caused by Hepatitis B virus (HBV)) and Hepatitis C (caused by Hepatitis C virus (HCV)). Anatolia Geneworks’ Bosphore Hepatitis kits provide in vitro diagnostic tools for detection, screening, quantification, and genotyping against HBV and HCV.
On World Liver Day, as Anatolia Geneworks we want to encourage everyone to take good care of their liver and show our support to fight against chronic liver diseases with our diagnostic tools.
#worldliverday #liver
…see more
Rate this translation
World Liver Day celebrated on the 19th of April, plays a vital role in raising awareness of chronic liver diseases.
The liver is one of the most vital organs in the human body, which performs more than 500 complex functions."
Charts are total rubbish. You can make read however you want !